•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A10467 Summary:

BILL NOA10467
 
SAME ASSAME AS S00396
 
SPONSORHyndman
 
COSPNSR
 
MLTSPNSR
 
Add §346, Ins L
 
Requires investigating of critical prescription drug pricing; provides for civil penalties and private actions for certain critical prescription drug pricing.
Go to top

A10467 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          10467
 
                   IN ASSEMBLY
 
                                      March 6, 2026
                                       ___________
 
        Introduced  by M. of A. HYNDMAN -- read once and referred to the Commit-
          tee on Insurance
 
        AN ACT to amend the insurance law, in relation to investigating critical
          prescription drug pricing
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section 1. The insurance law is amended by adding a new section 346 to
     2  read as follows:
     3    §  346.  Investigation  by the superintendent with respect to critical
     4  prescription drugs. (a) Whenever it shall appear to the  superintendent,
     5  either  upon complaint or otherwise, that in the advertisement, purchase
     6  or sale within this state of any critical prescription  drug,  that  the
     7  price  of  that critical prescription drug has increased over the course
     8  of any twelve months by more than the increase of  the  cost  of  living
     9  index for the list price of that critical prescription drug, or if it is
    10  suspected  that  any person, partnership, corporation, company, trust or
    11  association, or any agent or employee thereof has sold  or  offered  for
    12  sale  or  is  attempting  to  sell or is offering for sale  any critical
    13  prescription  drug  for which  the price of that drug has increased over
    14  the course of any twelve months by more than the increase of the cost of
    15  living index for the list price of that drug, or if  the  superintendent
    16  believes it is to the public interest to investigate, the superintendent
    17  shall  require  such person, partnership, corporation, company, trust or
    18  association, or any agent or employee thereof, to file with the  depart-
    19  ment  a statement in writing under oath or otherwise as to all the facts
    20  and circumstances concerning the price increase and for that purpose may
    21  prescribe forms upon which such statements shall be made.
    22    (b) In addition to any other power granted by law, the superintendent,
    23  their deputy or  other  officer  designated  by  the  superintendent  is
    24  empowered  to  subpoena witnesses, compel their attendance, examine them
    25  under oath and require the production of any books or papers which  they
    26  deem  relevant  or  material to the inquiry.  Such power of subpoena and
    27  examination shall not abate or terminate by  reason  of  any  action  or
    28  proceeding brought by the attorney general.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD01571-01-5

        A. 10467                            2
 
     1    (c)  No  person  shall  be  excused  from  attending  such  inquiry in
     2  pursuance to the mandates of a subpoena, or from producing  a  paper  or
     3  book,  or  from being   examined or required to answer a question on the
     4  ground of failure of tender or payment of a witness fee and/or  mileage,
     5  unless at the time of such appearance or production, as the case may be,
     6  such  witness  makes demand for such payment as a condition precedent to
     7  the offering of testimony or production required  by  the  subpoena  and
     8  unless such payment is not thereupon made. The provisions for payment of
     9  witness  fee  and/or mileage shall not apply to any officer, director or
    10  person in the employ of any person, partnership,  corporation,  company,
    11  trust or association whose conduct or practices are being investigated.
    12    (d)  If  a  person subpoenaed to attend such inquiry fails to obey the
    13  command of a subpoena without  reasonable  cause,  or  if  a  person  in
    14  attendance upon such inquiry shall without reasonable cause refuse to be
    15  sworn  or to be examined or to answer a question or to produce a book or
    16  paper when ordered so to do by the officer conducting such  inquiry,  or
    17  if  a  person, partnership, corporation,   company, trust or association
    18  fails to perform any act required by this section to be performed,  such
    19  person  shall be guilty of a misdemeanor and shall be subject to a civil
    20  penalty as set forth in subsection (e) of this section.
    21    (e) (1) If after an investigation authorized under  this  section  the
    22  superintendent determines that the increase in the price of the critical
    23  prescription  drug  is unjustified, the superintendent may, after notice
    24  and a hearing, levy a civil penalty not to exceed the greater of:
    25    (A) five thousand dollars for each offense;
    26    (B) a multiple of two times the aggregate damages attributable to  the
    27  offense; or
    28    (C)  a  multiple of two times the aggregate economic gain attributable
    29  to the offense.
    30    (2) If any person, partnership, corporation, company, trust or associ-
    31  ation, that fails to submit a written statement required by  the  super-
    32  intendent  under  subsection  (a) of this section or violates subsection
    33  (d) of this section, the superintendent may, after notice and a hearing,
    34  levy  a civil penalty not to exceed to one thousand dollars per day that
    35  such failure continues.
    36    (f) For the purposes of this section, a "critical  prescription  drug"
    37  shall be defined as one necessary to prevent or treat a disease or state
    38  in which death is possible or imminent.
    39    § 2. This act shall take effect immediately.
Go to top